Targeted therapies in oncology;Nouvelles thérapeutiques ciblées en oncologie

Revue du Praticien

Volumn 57, Issue 19, 2007, Pages 2093-2098

  Fournel Federico, Cécile ^a   You, Benoît ^b   Trillet Lenoir, Véronique ^b  

^a Institut de Cancerologie de la Loire   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYTARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FIBROBLAST GROWTH FACTOR 1; IMATINIB; IRINOTECAN; LAPATINIB; MONOCLONAL ANTIBODY; OXALIPLATIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PROTEIN; SORAFENIB; SUNITINIB; TRASTUZUMAB; TYVERB; UNCLASSIFIED DRUG; VASCULOTROPIN;

CELL PROLIFERATION; HUMAN; NEOPLASM; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 37749024764     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
2. Rankin C, Von Mehren M, Blanke C, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. Proc ASCO 2004. J Clin Oncol 2004;22:9005.
3. Blanke CD. Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate. Proc ASCO 2006. J Clin Oncol 2006;24:9528.
4. Slamon DJ, Clark GM, Wrong SG, et al. Human breast cancer, correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
6. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
7. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36.
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
10. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
11. Manegold C, von Pawel J, Zatloukal P, et al. Randomised,double- blind multicenter phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naive patients with advanced or recurrent non-squamous non-small cell lung cancer. J Clin Oncol 2007 ASCO;25:LBA7514.
12. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
13. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib combined with cisplatin and gemcitabine chemotherepy in advanced non-small-cell lung cancer. Proc ASCO 2004. J Clin Oncol 2004;22:7010.
14. Herbst RS, Prager D, Hermann R, et al. A phase III trial of erlotinib combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. Proc ASCO 2004. J Clin Oncol 2004;22:7011.
15. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
16. Motzer RJ, Huston TE, Tomczak P, et al. Sunitinib malate (SU11248) versus interferon-alfa (IFN-alpha) in metastatic renal cell carcinoma (mRCC). Proc ASCO 2006. J Clin Oncol 2006;24:LBA3.
17. Escudier B, Szczylik C, Eisen T, et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitorsorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc ASCO 2005. J Clin Oncol 2005;23:4510.
18. Demetri GD, Desai J, Fletcher JA, et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). Proc ASCO 2004. J Clin Oncol 2004;24:3001